Immunological analysis of the murine anti‐CD3‐induced cytokine release syndrome model and therapeutic efficacy of anti‐cytokine antibodies
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
The aberrant release of inflammatory mediators often referred to as a cytokine storm or cytokine release syndrome (CRS), is a common and sometimes fatal complication in acute infectious diseases including Ebola, dengue, COVID-19, and influenza. Fatal CRS occurrences have also plagued the development of highly promising cancer therapies based on T-cell engagers and chimeric antigen receptor (CAR) T cells. CRS is intimately linked with dysregulated and excessive cytokine release, including IFN-γ, TNF-α, IL 1, IL-6, and IL-10, resulting in a systemic inflammatory response leading to multiple organ failure. Here, we show that mice intravenously administered the agonistic hamster anti-mouse CD3ε monoclonal antibody 145-2C11 develop clinical and laboratory manifestations seen in patients afflicted with CRS, including body weight loss, hepatosplenomegaly, thrombocytopenia, increased vascular permeability, lung inflammation, and hypercytokinemia. Blood cytokine levels and gene expression analysis from lung, liver, and spleen demonstrated a hierarchy of inflammatory cytokine production and infiltrating immune cells with differentiating organ-dependent kinetics. IL-2, IFN-γ, TNF-α, and IL-6 up-regulation preceded clinical signs of CRS. The co-treatment of mice with a neutralizing anti-cytokine antibody cocktail transiently improved early clinical and laboratory features of CRS. We discuss the predictive use of this model in the context of new anti-cytokine strategies to treat human CRS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, drug-induced cytokine release syndrome has been studies in a humanized mouse model with success measured by observing clinical signs and elevated human cytokines (IL-6, IFN-γ, TNF-α) that mirror human CRS (Ye et al., 2020; Nouveau et al., 2021).”
From A large-scale concordance study of toxicity findings across preclinical species and humans for small molecules and biologics (2026) · cites this paper as Nouveau et al., 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
COVID-19: consider cytokine storm syndromes and immunosuppression
Mehta, P., McAuley, D. F., Brown, M., Sanchez, E., Tattersall, R. S., & Manson, J. J. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30628-0 · Cited by 9,664
Ruan, Q., Yang, K., Wang, W., Jiang, L., & Song, J. (2020) · Intensive Care Medicine · doi:10.1007/s00134-020-05991-x · Cited by 4,898
Clinical and immunological features of severe and moderate coronavirus disease 2019
Chen, G., Wu, D., Guo, W., Cao, Y., Huang, D., Wang, H., Wang, T., Zhang, X., Chen, H., Yu, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137244 · Cited by 4,750
SARS and MERS: recent insights into emerging coronaviruses
de Wit, E., van Doremalen, N., Falzarano, D., & Munster, V. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.81 · Cited by 3,510
Zhang, Y., & Zhang, Z. (2020) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-0488-6 · Cited by 2,794
Channappanavar, R., & Perlman, S. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0629-x · Cited by 2,524
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164
Into the Eye of the Cytokine Storm
Tisoncik, J. R., Korth, M. J., Simmons, C. P., Farrar, J., Martin, T. R., & Katze, M. G. (2012) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.05015-11 · Cited by 1,940
Cytokine release syndrome in severe COVID-19
Moore, J. B., & June, C. H. (2020) · Science · doi:10.1126/science.abb8925 · Cited by 1,912
Karki, R., Sharma, B. R., Tuladhar, S., Williams, E. P., Zalduondo, L., Samir, P., Zheng, M., Sundaram, B., Banoth, B., Malireddi, R. K. S., et al. (2021) · Cell · doi:10.1016/j.cell.2020.11.025 · Cited by 1,734
Liu, J., Li, S., Liu, J., Liang, B., Wang, X., Wang, H., Li, W., Tong, Q., Yi, J., Zhao, L., et al. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102763 · Cited by 1,702
Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & von Bergwelt-Baildon, M. S. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0343-9 · Cited by 1,656
A decade of immune-checkpoint inhibitors in cancer therapy
Robert, C. (2020) · Nature Communications · doi:10.1038/s41467-020-17670-y · Cited by 1,608
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
Stone, J. H., Frigault, M. J., Serling-Boyd, N. J., Fernandes, A. D., Harvey, L., Foulkes, A. S., Horick, N. K., Healy, B. C., Shah, R., Bensaci, A. M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028836 · Cited by 1,362
Qin, S., Rottman, J. B., Myers, P., Kassam, N., Weinblatt, M., Loetscher, M., Koch, A. E., Moser, B., & Mackay, C. R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1422 · Cited by 1,359
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)
Cossarizza, A., Chang, H., Radbruch, A., Acs, A., Adam, D., Adam‐Klages, S., Agace, W. W., Aghaeepour, N., Akdis, M., Allez, M., et al. (2019) · European Journal of Immunology · doi:10.1002/eji.201970107 · Cited by 979
SARS-CoV-2–triggered neutrophil extracellular traps mediate COVID-19 pathology
Veras, F. P., Pontelli, M. C., Silva, C. M., Toller-Kawahisa, J. E., de Lima, M., Nascimento, D. C., Schneider, A. H., Caetité, D., Tavares, L. A., Paiva, I. M., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201129 · Cited by 933
Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0028 · Cited by 873
The cytokine storm of severe influenza and development of immunomodulatory therapy
Liu, Q., Zhou, Y.-H., & Yang, Z.-Q. (2016) · Cellular & Molecular Immunology · doi:10.1038/cmi.2015.74 · Cited by 716
Sterner, R. M., Sakemura, R., Cox, M. J., Yang, N., Khadka, R. H., Forsman, C. L., Hansen, M. J., Jin, F., Ayasoufi, K., Hefazi, M., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881722 · Cited by 621
Gibson, P. G., Qin, L., & Puah, S. H. (2020) · Medical Journal of Australia · doi:10.5694/mja2.50674 · Cited by 598
Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology
Akwii, R. G., Sajib, M. S., Zahra, F. T., & Mikelis, C. M. (2019) · Cells · doi:10.3390/cells8050471 · Cited by 543
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
Locatelli, F., Jordan, M. B., Allen, C., Cesaro, S., Rizzari, C., Rao, A., Degar, B., Garrington, T. P., Sevilla, J., Putti, M.-C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911326 · Cited by 534
Hypercytokinemia in familial hemophagocytic lymphohistiocytosis
Henter, J., Elinder, G., Soder, O., Hansson, M., Andersson, B., & Andersson, U. (1991) · Blood · doi:10.1182/blood.v78.11.2918.2918 · Cited by 505
Luster, A. D., Greenberg, S. M., & Leder, P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.1.219 · Cited by 446
IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo.
Luster, A. D., & Leder, P. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1057 · Cited by 407
Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in mice
Behrens, E. M., Canna, S. W., Slade, K., Rao, S., Kreiger, P. A., Paessler, M., Kambayashi, T., & Koretzky, G. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43157 · Cited by 392
Wauquier, N., Becquart, P., Padilla, C., Baize, S., & Leroy, E. M. (2010) · PLoS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0000837 · Cited by 377
Cytokine Production Regulating Th1 and Th2 Cytokines in Hemophagocytic Lymphohistiocytosis
Osugi, Y., Hara, J., Tagawa, S., Takai, K., Hosoi, G., Matsuda, Y., Ohta, H., Fujisaki, H., Kobayashi, M., Sakata, N., et al. (1997) · Blood · doi:10.1182/blood.v89.11.4100 · Cited by 366
Chemokine CXCL1 mediated neutrophil recruitment: Role of glycosaminoglycan interactions
Sawant, K. V., Poluri, K. M., Dutta, A. K., Sepuru, K. M., Troshkina, A., Garofalo, R. P., & Rajarathnam, K. (2016) · Scientific Reports · doi:10.1038/srep33123 · Cited by 337
CHATENOUD, L., FERRAN, C., LEGENDRE, C., THOUARD, I., MERITE, S., REUTER, A., GEVAERT, Y., KREIS, H., FRANCHIMONT, P., & BACH, J.-F. (1990) · Transplantation · doi:10.1097/00007890-199004000-00009 · Cited by 320
In the eye of the COVID-19 cytokine storm
Vaninov, N. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0305-6 · Cited by 315
Multiple Roles for Chemokines in Neutrophil Biology
Capucetti, A., Albano, F., & Bonecchi, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01259 · Cited by 285
Immune-mediated cytokine storm and its role in severe dengue
Srikiatkhachorn, A., Mathew, A., & Rothman, A. L. (2017) · Seminars in Immunopathology · doi:10.1007/s00281-017-0625-1 · Cited by 267
Smadja, D. M., Guerin, C. L., Chocron, R., Yatim, N., Boussier, J., Gendron, N., Khider, L., Hadjadj, J., Goudot, G., Debuc, B., et al. (2020) · Angiogenesis · doi:10.1007/s10456-020-09730-0 · Cited by 252
Hartl, D., Krauss-Etschmann, S., Koller, B., Hordijk, P. L., Kuijpers, T. W., Hoffmann, F., Hector, A., Eber, E., Marcos, V., Bittmann, I., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.11.8053 · Cited by 236
Thomas, S. Y., Hou, R., Boyson, J. E., Means, T. K., Hess, C., Olson, D. P., Strominger, J. L., Brenner, M. B., Gumperz, J. E., Wilson, S. B., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.5.2571 · Cited by 229
Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19?
Panigrahy, D., Gilligan, M. M., Huang, S., Gartung, A., Cortés-Puch, I., Sime, P. J., Phipps, R. P., Serhan, C. N., & Hammock, B. D. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09889-4 · Cited by 219
Hirsch, R., Gress, R. E., Pluznik, D. H., Eckhaus, M., & Bluestone, J. A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.142.3.737 · Cited by 199
The storm has cleared: lessons from the CD28 superagonist TGN1412 trial
Hünig, T. (2012) · Nature Reviews Immunology · doi:10.1038/nri3192 · Cited by 194
Immunobiology of Ebola and Lassa virus infections
Prescott, J. B., Marzi, A., Safronetz, D., Robertson, S. J., Feldmann, H., & Best, S. M. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2016.138 · Cited by 147
Emapalumab: First Global Approval
Al-Salama, Z. T. (2019) · Drugs · doi:10.1007/s40265-018-1046-8 · Cited by 119
Cytokine Signature Associated with Disease Severity in Dengue
Patro, A. R. K., Mohanty, S., Prusty, B. K., Singh, D. K., Gaikwad, S., Saswat, T., Chattopadhyay, S., Das, B. K., Tripathy, R., & Ravindran, B. (2019) · Viruses · doi:10.3390/v11010034 · Cited by 109
Huarte, E., O’Connor, R. S., Peel, M. T., Nuñez-Cruz, S., Leferovich, J. M., Juvekar, A., Yang, Y., Truong, L., Huang, T., Naim, A. B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1739 · Cited by 109
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment
Yeleswaram, S., Smith, P. A., Burn, T. C., Covington, M. B., Juvekar, A., Li, Y., Squier, P., & Langmuir, P. B. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108517 · Cited by 97
Lacroix, M., Rousseau, F., Guilhot, F., Malinge, P., Magistrelli, G., Herren, S., Jones, S. A., Jones, G. W., Scheller, J., Lissilaa, R., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.682138 · Cited by 68
Self-citationInterferon-gamma coordinates CCL3-mediated neutrophil recruitment in vivo
Bonville, C. A., Percopo, C. M., Dyer, K. D., Gao, J., Prussin, C., Foster, B. A., Rosenberg, H. F., & Domachowske, J. B. (2009) · BMC Immunology · doi:10.1186/1471-2172-10-14 · Cited by 67
TAKADA, H., TAKAHATA, Y., NOMURA, A., OHGA, S., MIZUNO, Y., & HARA, T. (2003) · Clinical and Experimental Immunology · doi:10.1046/j.1365-2249.2003.02237.x · Cited by 67
Buatois, V., Chatel, L., Cons, L., Lory, S., Richard, F., Guilhot, F., Johnson, Z., Bracaglia, C., Benedetti, F. D., de Min, C., et al. (2016) · Translational research · doi:10.1016/j.trsl.2016.07.023 · Cited by 66
Self-citationResponse to 'Storm forecasting: additional lessons from the CD28 superagonist TGN1412 trial'
Hünig, T. (2012) · Nature reviews. Immunology · doi:10.1038/nri3192-c2 · Cited by 49
Limitations of neutrophil depletion by anti-Ly6G antibodies in two heterogenic immunological models
Pollenus, E., Malengier‐Devlies, B., Vandermosten, L., Pham, T., Mitera, T., Possemiers, H., Boon, L., Opdenakker, G., Matthys, P., & den Steen, P. E. V. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.06.006 · Cited by 46
Li, F., Yin, R., & Guo, Q. (2020) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466620905274 · Cited by 44
Angiopoietin-2: Modulator of Vascular Permeability in Acute Lung Injury?
Hashimoto, T. N., & Pittet, J. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030113 · Cited by 40
Tomescu, D. R., Dima, S., Ungureanu, D., Popescu, M., TULBURE, D., & Popescu, I. (2016) · The International Journal of Artificial Organs · doi:10.5301/ijao.5000489 · Cited by 32
Immunotherapy: A New Hope for Cancer Patients
Gupta, S. R., Gupta, S. C., Hunter, K. D., & Pant, A. B. (2020) · Journal of Oncology · doi:10.1155/2020/3548603 · Cited by 9
Cited by
Tvedt, T. H. A., Vo, A. K., Bruserud, Ø., & Reikvam, H. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215190 · Cited by 68
Napodano, C., Carnazzo, V., Basile, V., Pocino, K., Stefanile, A., Gallucci, S., Natali, P., Basile, U., & Marino, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316556 · Cited by 42
“…cytokine storm or cytokine release syndrome are characterized by elevated levels of circulating cytokines, immune hyperactivation, and multi-organ disfunction that can come to be fatal [93]. ammatory cytokines, fi rst IL-6, then interferon-γ and IL-1, have been in many cytokine storms [94–99].”
BackgroundCheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors
Broni, E., Ashley, C. N., Adams, J., Manu, H., Aikins, E., Okom, M., Miller, W. A., Wilson, M. D., & Kwofie, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076298 · Cited by 29
Seckinger, A., Majocchi, S., Moine, V., Nouveau, L., Ngoc, H., Daubeuf, B., Ravn, U., Plèche, N., Calloud, S., Broyer, L., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01516-3 · Cited by 24
“IFNγ, IL-6, and TNFα were measured as previously described [40, 41].”
MethodSelf-citationZhang, Z., Li, Y., Shi, J., Zhu, L., Dai, Y., Fu, P., Liu, S., Hong, M., Zhang, J., Wang, J., et al. (2022) · Aging and Disease · doi:10.14336/ad.2022.1102 · Cited by 21
“In addition, siponimod and anti-CD3 Abs (145-2C11) can also affect systemic immune responses by causing a reduction in peripheral lymphocytes and change in blood inflammatory biomarkers in vivo [84, 125, 127].”
Background
Metadata
- Authors
- Nouveau, L., Buatois, V., Cons, L., Chatel, L., Pontini, G., Pleche, N., & Ferlin, W. G.
- Affiliations
- Light Chain Bioscience (Switzerland) (CH)
- Light Chain Bioscience‐Novimmune S.A. Geneva Switzerland
- Corresponding author
- Ferlin, Walter G.
- Venue
- European Journal of Immunology
- Publisher
- Wiley
- Published
- 2021-05-19
- Volume
- 51
- Issue
- 8
- Pages
- 2074-2085
- ISSN
- 0014-2980 (ISSN-L)
- 1521-4141
- PMC
- PMC8237068
- OpenAlex
- W3157468375
- Cited by
- 25
- References
- 60
- Citations by year
- 2026: 8 · 2025: 1 · 2024: 5 · 2023: 6 · 2022: 4 · 2021: 1
- FWCI
- 2.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- European Journal of Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
- Keywords
- cytokine release syndrome, CD3ε, interleukin-6, interferon-gamma, TNF-α, interleukin-2, cytokine storm, T-cell engagers, CAR T-cell therapy, systemic inflammatory response, lung inflammation, hepatosplenomegaly, thrombocytopenia, vascular permeability, cytokine gene expression
- MeSH terms
- Cytokine Release Syndrome, Animals, Antibodies, Antibodies, Monoclonal, Disease Models, Animal, Drug Therapy, Combination, Lymphocyte Activation, Phenotype, Severity of Illness Index, T-Lymphocytes, Cytokines, Treatment Outcome, CD3 Complex, Inflammation Mediators, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.